Search

Henry M Sarau

from Green Lane, PA
Age ~85
Get Report
Also known as:
Henry Dr Sarau, Henry S Sarau, Carol A Sarau, Henry M Sarou, Henry Sadau
Phone and address:
2844 Hill Rd, Green Lane, PA 18054
(215) 234-8510
Related to:
Devon JamesChristopher JamesCalen Kim, 50Samantha Sarau, 34Brandon James, 33
Connected to:
Shelby A Sarauer, 63Albert A Saraullo, 81Eric T Sarault, 52John M Sarausad, 42Joshua J Sarauw, 38Aditya Saravagi, 40Bhavani Saravanan, 46Karen K Saravanos, 58Karthik B Saravana, 39Natarajan Saravanan, 48

Henry Sarau Phones & Addresses

  • 2844 Hill Rd, Green Lane, PA 18054 (215) 234-8510
  • 348 Maple Ave, Harleysville, PA 19438 (215) 256-1027
  • Hatfield, PA
  • Hereford, PA
  • Lehighton, PA
  • Kulpsville, PA
  • Montgomery, PA
  • 76 Spring Hill Rd, Hereford, PA 18056 (215) 266-8377

Work

Position: Service Occupations

Education

Degree: High school graduate or higher

Emails

h***[email protected]

Publications

Us Patents

Molecular Cloning Of A 7Tm Receptor (Axor34) And Screening Methods Thereof

View page
US Patent:
6461836, Oct 8, 2002
Filed:
Apr 10, 2000
Appl. No.:
09/545944
Inventors:
Nabil Elshourbagy - West Chester PA
Usman Shabon - Collegeville PA
Robert S. Ames - Havertown PA
Henry S. Sarau - Harleysville PA
Lisa Vawter - Coopersburg PA
David Michalovich - Harlow, GB
Assignee:
SmithKline Beecham Corporation - Philadelphia PA
SmithKline Beecham p.l.c. - Brentford
International Classification:
C12N 1512
US Classification:
435 691, 4353201, 435325, 536 235, 530350
Abstract:
AXOR34 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR34 polypeptides and polynucleotides in diagnostic assays. Further disclosed are screening assays to identify agonists and antagonists of the interaction between AXOR34 and its ligands, NmU-8, NmU-25, and NmU-23.

Hmtf81 Human 7-Transmembrane Receptor

View page
US Patent:
6506878, Jan 14, 2003
Filed:
Jun 5, 2000
Appl. No.:
09/586924
Inventors:
Catherine E. Ellis - Glassboro NJ
Wendy Halsey - Kennett Square PA
Ganesh M. Sathe - King of Prussia PA
Robert S. Ames - Havertown PA
James J. Foley - Radnor PA
Henry M. Sarau - Harleysville PA
Jon Chambers - Haslingfield, GB
Assignee:
Smithkline Beecham Corporation - Philadelphia PA
International Classification:
C07K 14705
US Classification:
530350, 435 691, 435 711, 435 712, 435325, 435471, 4352523, 43525411, 4353201
Abstract:
HMTMF81 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HMTMF81 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinsons disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntingtons disease or Gilles dela Touretts syndrome, among others and diagnostic assays for such conditions.

Molecular Cloning Of A 7Tm Receptor (Axor34) And Screening Methods Thereof

View page
US Patent:
6881827, Apr 19, 2005
Filed:
Aug 9, 2002
Appl. No.:
10/215619
Inventors:
Nabil Elshourbagy - West Chester PA, US
Usman Shabon - Collegeville PA, US
Robert S. Ames - Havertown PA, US
Henry S. Sarau - Harleysville PA, US
Lisa Vawter - Coopersburg PA, US
David Michalovich - Harlow, GB
Assignee:
SmithKline Beecham Corporation - Philadelphia PA
SmithKline Beecham p.l.c. - Middlesex
International Classification:
C07K014/00
C07K001/00
US Classification:
530350
Abstract:
AXOR34 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR34 polypeptides and polynucleotides in diagnostic assays. Further disclosed are screening assays to identify agonists and antagonists of the interaction between AXOR34 and its ligands, NmU-8, NmU-25, and NmU-23.

Method Of Finding Agonist And Antagonist To Human 11Cb Splice Variant

View page
US Patent:
20020038007, Mar 28, 2002
Filed:
Aug 9, 2001
Appl. No.:
09/925776
Inventors:
Robert Ames - Haverford PA, US
Henry Sarau - Harleysville PA, US
James Foley - Radnor PA, US
Derk Bergsma - Berwyn PA, US
Catherine Ellis - Glassboro NJ, US
Jon Chambers - Harlow, GB
International Classification:
C07H021/04
G01N033/53
A61K048/00
A61K038/17
C12N005/06
C12P021/02
C12N015/74
US Classification:
536/023100, 435/007100, 435/325000, 435/455000, 435/069100, 435/320100, 514/044000, 514/012000, 530/388100
Abstract:
Human 11cb splice variant polypeptides and DNA (RNA) encoding such an 11cb splice variant and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such an 11cb splice variant for the treatment of to treat infections, such as bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; diabetes; obesity; feeding and drinking abnormalities, such as anorexia and bulimia; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation, and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome; among others,. Antagonists against such an 11cb splice variant and their use as a therapeutic to treat to treat infections, such as bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; diabetes; obesity; feeding and drinking abnormalities, such as anorexia and bulimia; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation, and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome; among others, are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the 11cb splice variant and for detecting altered levels of the polypeptide in a host.

G-Protein Coupled Receptor Hnfds78 Polypeptides

View page
US Patent:
20020076760, Jun 20, 2002
Filed:
Jul 24, 2001
Appl. No.:
09/912025
Inventors:
Derk Bergsma - Berwyn PA, US
Nabil Elshourbagy - West Chester PA, US
Henry Sarau - Harleysville PA, US
Steven Ruben - Olney MD, US
International Classification:
C07K014/705
C12P021/02
C12N005/06
A61K031/00
G01N033/53
C07H021/04
C12N015/74
US Classification:
435/069100, 435/320100, 435/455000, 435/325000, 435/007100, 536/023500, 530/350000, 514/001000
Abstract:
Human G-Protein Coupled Receptor HNFDS78 polypeptides and DNA (RNA) encoding such G-Protein Coupled Receptor HNFDS78 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such G-Protein Coupled Receptor HNFDS78 for the treatment of diseases, such as, atherosclerosis, inflammatory disease, and infectious disease. Antagonists against such G-Protein Coupled Receptor HNFDS78 and their use as a therapeutic to treat disease are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding G-protein coupled receptors and for detecting altered levels of the polypeptide in a host.

Methods Of Screening For Agonists And Agonists Of The Interaction Between The Axor8 And Axor52 Receptors And Ligands Thereof

View page
US Patent:
20030059856, Mar 27, 2003
Filed:
Apr 25, 2002
Appl. No.:
10/132812
Inventors:
Robert Ames - Haverford PA, US
Henry Sarau - Harleysville PA, US
J. Slemmon - Glenview IL, US
Dean McNulty - Philadelphia PA, US
Lisa Vawter - Coopersburg PA, US
James Foley - Radnor PA, US
International Classification:
G01N033/567
US Classification:
435/007210
Abstract:
Disclosed are methods for discovering agonists and antagonists of the interaction between monkey AXOR8, human AXOR8, and human AXOR52 receptors with their natural ligands: human BV8-a, mouse BV8-a, frog BV8, human BV8-b, human PRO1186, human PRO1186 variant, and mamba intestinal toxin (herein “MIT”). Such agonists or antagonists can be used in the treatment of several human diseases and disorders, including, but not limited to: bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome.

Imidazolium Cxcr3 Inhibitors

View page
US Patent:
20050272936, Dec 8, 2005
Filed:
May 29, 2003
Appl. No.:
10/516970
Inventors:
Jeffrey Axten - Collegeville PA, US
James Foley - King of Prussia PA, US
William Kingsbury - Collegeville PA, US
Henry Sarau - King of Prussia PA, US
International Classification:
C07D233/54
C07D043/02
US Classification:
548311100, 548335100, 548341100
Abstract:
Imidazolium compounds of formula I compound of formula (I) wherein:

Method Of Treatment

View page
US Patent:
20100256157, Oct 7, 2010
Filed:
Mar 19, 2010
Appl. No.:
12/727488
Inventors:
Jakob Busch-Petersen - King of Prussia PA, US
Thomas B. LEONARD - Ridgefield CT, US
Michael R. Palovich - King Of Prussia PA, US
Henry M. Sarau - Green Lane PA, US
Aili L. Lazaar - King of Prussia PA, US
Katherine L. Widdowson - Collegeville PA, US
International Classification:
A61K 31/495
A61P 1/18
A61P 11/00
US Classification:
51425212
Abstract:
This invention relates to the use of a sulfonamide substituted diphenyl urea compound to treat cystic fibrosis, or the symptoms associated with cystic fibrosis.
Control profile
Henry M Sarau from Green Lane, PA, age ~85 Get Report